Supplementary Materials to the Financial Results — First Quarter of the Fiscal Year Ending December 2026 | Kyowa Kirin Co.,Ltd. (4151) timely disclosure

Worth reading

66In focus

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Improvement

Direction inferred from the company’s description.

Scale

137

¥ million

Wording

Avoiding a definitive answer

How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportFirst quarter of the fiscal year ending December 20268 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales¥1,185 million+13.0%

Operating profit¥200 100 million +78.0%core operating profit

Ordinary income¥139 100 million +77.0%profit before tax for the quarter

Net income¥120 100 million +95.0%profit for the quarter

Selling, general and administrative expenses¥411 100 million expense

Gross Profit Margin

Rate74.5%

Operating profit margin

Rate16.9% (core operating margin)

Results for the three months of the current quarter

Revenue¥118.5 billion (up 13% year on year)

Core operating profit¥20.0 billion (up 78% year on year)

Profit before quarterly income taxes¥13.9 billion (up 77% year on year)

Quarterly profit¥12.0 billion (up 95% year on year)

Core profit for the period¥17.3 billion (up 96% year on year)

Full-year earnings forecast

Revenue¥520.0 billion

Gross profit¥388.0 billion

Selling, general and administrative expenses¥163.0 billion (expense)

Research and development costs¥95.0 billion (expense)

Core operating profit¥130 billion

Income before taxes¥95.0 billion

Profit for the period¥75 billion

Core profit for the period¥103.0 billion

Core EPS¥196.76 per share

Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。

Revenue23%

Gross profit23%

Selling, general and administrative expenses25%

Research and development costs29%

Core operating profit15%

Income before taxes15%

Profit for the period16%

Core profit for the period17%

Revenue by regional headquarters company

Japan24%

North America17%

EMEA29%

Other28%

Products and merchandise21%

Technology income33%

Crysvita19%

Poteligeo22%

Libmeldy / Lenmeldy15%

What the company explained in this material

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Revenue by regional headquarters company

Japan-9

North America7

EMEA34

Other106

Revenue from major products

Crysvita32

Poteligeo23

Libmeldy / Lenmeldy-6

Technology income119

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

US dollars¥150

British pound¥205 per pound sterling

Euro¥180

New initiatives

For ziftomenib, dosing of the first patient in a Phase II study in Japan for relapsed or refractory AML began on 24 April 2026.
Information on KHK4083 / AMG 451 (rocatinlimab) was removed from the development pipeline following the discontinuation of its clinical trials.

Key KPIsA metric the company considers important as a management benchmark.

Overseas Revenue Mix77 %
Year on year against the same period last yearUp 4 percentage points year on year
R&D expense ratio22.9 %
Core EPS¥33.04 per share
ROE7.7 %
DOE3.8 %

Segment results

By regional headquarters company

Japan

Revenue¥26.2 billion

Year on year against the same period last yearDown ¥0.9 billion year on year

North America

Revenue¥36.2 billion

Year on year against the same period last yearUp ¥0.7 billion year on year

EMEA

Revenue¥23.1 billion

Year on year against the same period last yearUp ¥3.4 billion year on year

Other

Revenue¥32.9 billion

Year on year against the same period last yearUp ¥10.6 billion year on year

Financial targets

ROE8.2% (2026 forecast)

ROE (three-year average)7.7% (2026 forecast; three-year average)

DOE4.1% (2026 forecast)

Number of employees

Number of Employees5,165 employees (as of the end of March 2026)

Change during the periodDown 355 employees during the period

Capital expenditures

¥108 100 million total capital expenditures and intangible asset investments

Contents of this document
Item	Details
Document type	Supplementary materials to the earnings report
Fiscal Period Covered	First quarter of the fiscal year ending December 2026
Net Sales	¥1,185 million (YoY +13.0%)
Operating profit	¥200 100 million (core operating profit) (YoY +78.0%)
Ordinary income	¥139 100 million (profit before tax for the quarter) (YoY +77.0%)
Net income	¥120 100 million (profit for the quarter) (YoY +95.0%)
Gross Profit Margin	Rate 74.5% / Year-on-year change (points) Not disclosed
Operating profit margin	Rate 16.9% (core operating margin) / Year-on-year change (points) Not disclosed
Selling, general and administrative expenses	¥411 100 million (expense)
Results for the three months of the current quarter	Revenue ¥118.5 billion (up 13% year on year) / Core operating profit ¥20.0 billion (up 78% year on year) / Profit before quarterly income taxes ¥13.9 billion (up 77% year on year) / Quarterly profit ¥12.0 billion (up 95% year on year) / Core profit for the period ¥17.3 billion (up 96% year on year)
Full-year earnings forecast	Revenue ¥520.0 billion / Gross profit ¥388.0 billion / Selling, general and administrative expenses ¥163.0 billion (expense) / Research and development costs ¥95.0 billion (expense) / Core operating profit ¥130 billion / Income before taxes ¥95.0 billion / Profit for the period ¥75 billion / Core profit for the period ¥103.0 billion / Core EPS ¥196.76 per share
Progress against full-year forecast	Revenue 23% / Gross profit 23% / Selling, general and administrative expenses 25% / Research and development costs 29% / Core operating profit 15% / Income before taxes 15% / Profit for the period 16% / Core profit for the period 17% / Revenue by regional headquarters company Japan 24% / North America 17% / EMEA 29% / Other 28% / Products and merchandise 21% / Technology income 33% / Crysvita 19% / Poteligeo 22% / Libmeldy / Lenmeldy 15%
Segment results	By regional headquarters company Japan Revenue ¥26.2 billion / Year on year against the same period last year Down ¥0.9 billion year on year / North America Revenue ¥36.2 billion / Year on year against the same period last year Up ¥0.7 billion year on year / EMEA Revenue ¥23.1 billion / Year on year against the same period last year Up ¥3.4 billion year on year / Other Revenue ¥32.9 billion / Year on year against the same period last year Up ¥10.6 billion year on year
Breakdown of Factors Affecting the Change	Revenue by regional headquarters company Japan -9 / North America 7 / EMEA 34 / Other 106 / Revenue from major products Crysvita 32 / Poteligeo 23 / Libmeldy / Lenmeldy -6 / Technology income 119
Key KPIs	Indicator name Overseas Revenue Mix / Value 77 % / Year on year against the same period last year Up 4 percentage points year on year, Indicator name R&D expense ratio / Value 22.9 % / Year on year against the same period last year Not disclosed, Indicator name Core EPS / Value ¥33.04 per share / Year on year against the same period last year Not disclosed, Indicator name ROE / Value 7.7 % / Year on year against the same period last year Not disclosed, Indicator name DOE / Value 3.8 % / Year on year against the same period last year Not disclosed
Number of employees	Number of Employees 5,165 employees (as of the end of March 2026) / Change during the period Down 355 employees during the period
Assumptions Underlying the Business Outlook	US dollars ¥150 / British pound ¥205 per pound sterling / Euro ¥180
Financial targets	ROE 8.2% (2026 forecast) / ROE (three-year average) 7.7% (2026 forecast; three-year average) / DOE 4.1% (2026 forecast)
Capital expenditures	¥108 100 million (total capital expenditures and intangible asset investments)
New initiatives	For ziftomenib, dosing of the first patient in a Phase II study in Japan for relapsed or refractory AML began on 24 April 2026., Information on KHK4083 / AMG 451 (rocatinlimab) was removed from the development pipeline following the discontinuation of its clinical trials.

Items this document does not state (11)

Self-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

By product, revenue increases were reported for Crysvita, Poteligeo and technology income. However, no written summary was provided of the overall factors behind the increase or decrease in results.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.